We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





Harvard-Designed Injection-Molded Nasopharyngeal Swabs For COVID-19 Enter Human Trials

By LabMedica International staff writers
Posted on 30 Apr 2020
Researchers at the Wyss Institute at Harvard University (Boston, MA, USA) have designed a new, fully injection-molded nasopharyngeal swab that can be manufactured quickly and inexpensively at high volume to help address the shortage of swabs for COVID-19 testing and research.

While other teams have leveraged 3D printing, the Wyss team set out to create a new design that could be manufactured using injection molding rather than 3D printing, because injection molding is faster, less expensive, and is routinely used by a broad range of experienced medical device manufacturers worldwide. More...
Initially, the Wyss team developed and tested new swab designs that they 3D printed to eventually settle on a design with a flexible, honey-dipper-like tip that could be injection-molded.

The Wyss team has now sent prototype injection-molded swabs to eight hospitals and health centers for preclinical testing, in which clinicians are evaluating the swabs' performance on a variety of fronts including their comfort and ease of use, as well as their ability to collect a large enough sample with detectable amounts of viral RNA.

The swabs are now being tested in human subjects who will receive a normal swab in one nostril and a prototype of the Wyss-designed swab in the other. If the new swabs can collect a sample that contains detectable genetic information while being as easy-to-use and comfortable as the existing swabs, IPB will ramp up production of the final injection-molded design, which will be used in future clinical trials and, the team hopes, become widely adopted by the medical community in testing patients for COVID-19. Meanwhile, medical device manufacturer IPB, Inc. has been working around the clock to ramp up production of the new swabs to reach 200,000 per day by May 15.

"Experts have recently estimated that the United States needs to more than triple the number of daily COVID-19 tests in order for the country to be safely reopened by mid-May, but the current swabs are complicated to make, and producers just don't have the ability to increase production to that level in such a short period of time," said Richard Novak, Ph.D., a Senior Staff Engineer at the Wyss Institute who has been leading the multi-institutional effort to develop a fully injection-molded swab, working with the Wyss Institute's Founding Director Donald Ingber, M.D., Ph.D. "These new swabs can help meet the critical need for collecting samples, both to diagnose patients and to study the virus itself so that treatments and a vaccine can be found sooner."

Related Links:
Wyss Institute at Harvard University


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple daily blood test could help critically ill sepsis patients stop antibiotics sooner, reducing overuse and potentially helping combat antibiotic resistance (Image Credit: Adobe Stock)

Daily Blood Biomarker Testing May Help Guide Earlier Antibiotic Stopping in Sepsis

Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.